A Phase 3 interventional study of Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets and Paracetamol (500 mg) tablets in Upper Respiratory Tract Infection, Nasal Congestion and Rhinorrhea, sponsored by Novartis. Completed at 6 sites in Brazil. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-03-03.
Sponsored by Novartis · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Common Cold with a site in Brazil — 1 open to participants now, 1 under way, 1 of them phase 3. Common Cold · Brazil.
Among the 12 studies in Common Cold with a site in Brazil, this one is the 4th largest by enrollment, is the only one that started in 2013, is one of 11 in phase 3, and was the 7th registered.
219 studies on the registry are indexed under Common Cold; 23 are open to participants now.
Browse Common Cold studies →1 of the 12 studies in Common Cold with a site in Brazil is open now. Recruiting first, the newest first:
Brainfarma Industria Química e Farmacêutica S/A · Sites in Brazil
Ages 18–60
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 14 Common Cold studies recruiting now, 4 (29%) set no upper age limit and 9 (64%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 341 is above the median of 150 across 184 interventional studies indexed under Common Cold.
Median enrollment 183 across the 12 interventional studies. Of the 5 that completed or were terminated, 1 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 12 have an industry lead sponsor. The 7 most frequent:
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
Novartis has 4 studies filed under Common Cold — fewer than ten, so there is no comparison to draw.
1 of the studies in Common Cold with a site in Brazil that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07626437Phase 3Brainfarma Industria Química e Farmacêutica S/AFixed-dose Combination of 1000 mg Dipyrone Monohydrate + 60 mg Caffeine + 4 mg Chlorpheniramine Maleate in Improving Symptoms of the Common Cold and Flu in Adults | 2027-06-28 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Common Cold with a site in Brazil, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study is a clinical evaluation of an over the counter (OTC) combination product containing paracetamol (500 mg), dimethindene maleate (1 mg), phenylephrine hydrochloride (10 mg) compared to paracetamol (500 mg) alone in the treatment of nasal congestion, rhinorrhea, sneezing and other symptoms due to upper respiratory tract infection (URTI).
219 studies on the registry are indexed under Common Cold; 23 are open to participants now.
This study's enrollment of 341 is above the median of 150 across 184 interventional studies indexed under Common Cold.
Browse Common Cold studies →Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
Compared within Common Cold, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Respiratory Tract Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Use of other drugs within 30 days or 10 half-lives before enrollment, whichever is longer.
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets
Drug: Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets
Paracetamol (500 mg) tablets
Drug: Paracetamol (500 mg) tablets
Drug pages: Acetaminophen · Dimethindene · Phenylephrine
Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets
Paracetamol (500 mg) tablets
Physician Global Evaluation of Effectiveness on Nasal Symptoms
The Physician will measure the reduction of Nasal Symptoms (Nasal Congestion, Sneezing, and Rhinorrhea) on day 2. Range from 1 to 5 where 1 is excellent and 5 is bad : 1 = excellent : 75% to 100% remission of signs and symptoms 5 = bad : exacerbation of nasal symptoms
Time frame: Day 2
Daily Average of the Sum of a 100 mm Visual Analog Scale for All Symptoms
Subject will assess Nasal and non Nasal symptoms using a 100 mm Visual Analog Scale for each symptom, 0=no symptoms 100= the worst possible symptoms
Time frame: Day 3
| Milestone | Combination Product | Paracetamol Tablets |
|---|---|---|
| Started | 170 | 171 |
| Completed | 162 | 167 |
| Not completed | 8 | 4 |
| Withdrew: Protocol violation | 3 | 2 |
| Withdrew: Lost to follow-up | 3 | 0 |
| Withdrew: Adverse event | 0 | 2 |
| Withdrew: Withdrawal by subject | 2 | 0 |
The Physician will measure the reduction of Nasal Symptoms (Nasal Congestion, Sneezing, and Rhinorrhea) on day 2. Range from 1 to 5 where 1 is excellent and 5 is bad : 1 = excellent : 75% to 100% remission of signs and symptoms 5 = bad : exacerbation of nasal symptoms
| score on a scale | Arm A | Arm B |
|---|---|---|
| Physician Global Evaluation of Effectiveness on Nasal Symptoms | 1.9 ± 0.84 | 2.1 ± 0.91 |
Subject will assess Nasal and non Nasal symptoms using a 100 mm Visual Analog Scale for each symptom, 0=no symptoms 100= the worst possible symptoms
| mm | Arm A | Arm B |
|---|---|---|
| Daily Average of the Sum of a 100 mm Visual Analog Scale for All Symptoms | 169.2 ± 231.14 | 225.3 ± 262.59 |
Collected over 3 days. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A | — | 0/170 (0%) | 77/170 (45.3%) |
| Arm B | — | 0/171 (0%) | 39/171 (22.8%) |
| Event | Arm A | Arm B |
|---|---|---|
| somnolenceNervous system disorders | 71/170 | 37/171 |
| Abdominal painGastrointestinal disorders | 6/170 | 2/171 |
| Age, Categorical(Participants) | Arm A | Arm B | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 170 | 171 | 341 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | Arm A | Arm B | Total |
|---|---|---|---|
| Mean | 36 ± 11.64 | 34.5 ± 11.76 | 35.3 ± 11.71 |
| Gender(Participants) | Arm A | Arm B | Total |
|---|---|---|---|
| Female | 122 | 134 | 256 |
| Male | 48 | 37 | 85 |
| Region of Enrollment(participants) | Arm A | Arm B | Total |
|---|---|---|---|
| Brazil | 170 | 171 | 341 |
The record gives a start of Jul 2013, a primary completion of Aug 2015 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2017, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Acetaminophen · Dimethindene · Phenylephrine